However, injection of two doses of RGR-TRAIL only showed mild tumor growth suppression in mice bearing HT29 tumor xenografts (Figure 3(F)), suggesting that the level of DR in these CRC cells was crucial for the antitumor effect of RGR-TRAIL; thus, increasing the DR level might sensitize HT29 cells to RGR-TRAIL. The gene discussed is TNFSF10; the disease is colorectal carcinoma.